• SPX
  • $5,969.42
  • 0.35 %
  • $20.71
  • DJI
  • $44,200.10
  • 0.75 %
  • $329.74
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,263.47
  • 1.4 %
  • $114.20
  • IXIC
  • $18,991.44
  • 0.1 %
  • $19.02
Travere Therapeutics, Inc. (TVTX) Stock Price, News & Analysis

Travere Therapeutics, Inc. (TVTX) Stock Price, News & Analysis

Currency in USD Disclaimer

$18.55

$0.29

(1.6%)

Day's range
$18.03
Day's range
$18.55
50-day range
$13.22
Day's range
$20.33
  • Country: US
  • ISIN: US89422G1076
52 wk range
$5.12
Day's range
$20.33


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.55
  • Piotroski Score 4.00
  • Grade Overweight
  • Symbol (TVTX)
  • Company Travere Therapeutics, Inc.
  • Price $18.55
  • Changes Percentage (1.6%)
  • Change $0.29
  • Day Low $18.03
  • Day High $18.55
  • Year High $20.33

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $21.50
  • High Stock Price Target $33.00
  • Low Stock Price Target $12.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$5.41
  • Trailing P/E Ratio -1.32
  • Forward P/E Ratio -1.32
  • P/E Growth -1.32
  • Net Income $-111,399,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Travere Therapeutics, Inc. Frequently Asked Questions

  • What is the Travere Therapeutics, Inc. stock price today?

    Today's price of Travere Therapeutics, Inc. is $18.55 — it has increased by +1.6% in the past 24 hours. Watch Travere Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Travere Therapeutics, Inc. release reports?

    Yes, you can track Travere Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Travere Therapeutics, Inc. stock forecast?

    Watch the Travere Therapeutics, Inc. chart and read a more detailed Travere Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Travere Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Travere Therapeutics, Inc. stock ticker.

  • How to buy Travere Therapeutics, Inc. stocks?

    Like other stocks, TVTX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Travere Therapeutics, Inc.'s EBITDA?

    Travere Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Travere Therapeutics, Inc.’s financial statements.

  • What is the Travere Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.7670100112, which equates to approximately -76.70%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Travere Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Travere Therapeutics, Inc.'s financials relevant news, and technical analysis. Travere Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Travere Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Travere Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Travere Therapeutics, Inc. for its last quarter?

    Travere Therapeutics, Inc. published it's last quarterly revenues at $62.90 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.